Abiopharma

🔍 Simmons James H. III (Executive)

Company: REGENCY CENTERS CORP (REG)

Report Date: 2026-05-11

Detailed Transactions and Holdings:

• Acquired 1,736 shares of Common Stock (Direct)
  Date: 2026-05-11 | Code: M | equity_swap_involved: false | shares_owned_after: 7,978.00 | transaction_form_type: 4 | Footnotes: F1
• Acquired 71 shares of Common Stock (Direct)
  Date: 2026-05-11 | Code: M | equity_swap_involved: false | shares_owned_after: 8,049.00 | transaction_form_type: 4 | Footnotes: F2
• Sold 1,736 shares of Restricted Stock (Derivative)
  Date: 2026-05-11 | Code: M | equity_swap_involved: false | transaction_form_type: 4 | Footnotes: F1, F1
• Sold 71 shares of Dividend Equivalent Rights (Derivative)
  Date: 2026-05-11 | Code: M | equity_swap_involved: false | transaction_form_type: 4 | Footnotes: F2, F2

Footnotes:

• F1: Vesting of restricted stock grant pursuant to Regency's Omnibus Incentive Plan.
• F2: Settlement of dividend equivalent rights in connection with vesting of restrictive stock. The rights accrued when and as dividends were paid on Regency's common stock and vested proportionately with the restricted stock. Each dividend equivalent is the equivalent of one share of Regency's common stock.